Natural History of Levodopa-Induced Dyskinesia (LID)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01003002 |
Recruitment Status :
Withdrawn
(Funding not secured.)
First Posted : October 28, 2009
Last Update Posted : April 6, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Parkinson's Disease | Drug: Levodopa (delivered intravenously) |
Study Type : | Observational |
Actual Enrollment : | 0 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Determining the Natural History of Levodopa-Induced Dyskinesia (LID) |
Study Start Date : | December 2010 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | December 2020 |

Group/Cohort | Intervention/treatment |
---|---|
PD Cohort
The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
|
Drug: Levodopa (delivered intravenously)
One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100. |
- Levodopa-Induced Dyskinesia [ Time Frame: 5 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Diagnosis of Parkinson's disease
- At least 21 years of age
- Levodopa treatment that will be orally initiated no more than 1 month after the screening visit for the study.
Exclusion Criteria:
- Unable to stand for 1 minute intervals
- Sensory deficits in the feet
- Significant cognitive impairment
- Unstable medical or psychiatric conditions (including hallucinations)
- History of dopamine receptor blocking medications (Haldol, Orap, Zyprexa)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01003002
United States, Oregon | |
Oregon Health & Science University | |
Portland, Oregon, United States, 97239 |
Principal Investigator: | Kathryn Chung, MD | Oregon Health and Science University |
Responsible Party: | Kathryn Chung, MD, Oregon Health & Science University |
ClinicalTrials.gov Identifier: | NCT01003002 |
Other Study ID Numbers: |
e4773 |
First Posted: | October 28, 2009 Key Record Dates |
Last Update Posted: | April 6, 2016 |
Last Verified: | October 2009 |
Parkinson's disease Dyskinesia Movement Disorders |
Parkinson Disease Dyskinesias Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Synucleinopathies |
Neurodegenerative Diseases Neurologic Manifestations Levodopa Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |